%0 Journal Article %T The DESolve novolimus bioresorbable Scaffold: from bench to bedside %A Mattesini, Alessio %A Bartolini, Simone %A Dini, Carlotta Sorini %A Valente, Serafina %A Parodi, Guido %A Stolcova, Miroslava %A Meucci, Francesco %A Mario, Carlo Di %J Journal of Thoracic Disease %D 2017 %B 2017 %9 %! The DESolve novolimus bioresorbable Scaffold: from bench to bedside %K %X The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and in vitro bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3- to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment. Overexpansion with DESolve is safe since a high capability resistance to fracture has been demonstrated with this scaffold. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding the DESolve. %U https://jtd.amegroups.org/article/view/14886 %P S950-S958 %@ 2077-6624